Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a penchant for ASX growth shares like I do, then read on!

That's because the two in this article have not only been named as buys but have been tipped to rise at least 30% from current levels. Here's what analysts are saying about them:

Life360 Inc (ASX: 360)

The team at Goldman Sachs thinks that this location technology company could be a quality ASX growth share to buy now.

It has a buy rating and $27.00 price target on its shares. This suggests that upside of 30% is possible for investors between now and this time next year.

The broker likes Life360 due to its huge total addressable market (TAM) and significant user monetisation opportunity. It explains:

We estimate Life360 is exposed to a US$12bn global TAM with a large opportunity to expand its product suite, grow average revenue per paying circle (ARPPC), increase payer conversion, and lift penetration rates outside of the US. The company has demonstrated its pricing power and is now exploring the latent monetisation opportunity of its >60mn user base via advertising.

Goldman also highlights that its shares are undervalued compared to peers. It adds:

 Life360's Subscription business currently trades at a discount to global subscription app peers when adjusting for its superior growth outlook. We see scope for re-rating as Life360 demonstrates operating leverage, ongoing subscription growth and user monetisation via ads. We are Buy rated on Life360.

Pro Medicus Limited (ASX: PME)

Bell Potter thinks that this health imaging technology company could be an ASX growth share to buy.

Its analysts have put a buy rating and $280.00 price target on its shares. Based on its current share price, this implies potential upside of 33% over the next 12 months.

Commenting on the company, the broker said:

Pro medicus is a leading health imaging IT provider. It's leading product is the Visage 7 Enterprise Viewer (the Visage Viewer). It is an essential component of a modern PACS with its main advantage being speed. Using this system the radiologist is able to view medical images from all major modalities at lightning fast speed including prior exams.

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A businessman compares the growth trajectory of property versus shares.
Growth Shares

The ASX stocks I think could define the next decade of growth

Analysts are recommending these growth machines to clients.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Growth Shares

Top Australian stocks to buy right now with $2,000

There are good reasons why these shares are rated as buys by brokers.

Read more »

Piggybank with an army helmet and a drone next to it, symbolising a rising DroneShield share price.
Growth Shares

The sleeper defence stock set to explode? Up 240% in 2025, and poised to fire again!

A big part of the EOS story this year comes down to how quickly modern warfare is changing.

Read more »

a man sits on a ridge high above a large city full of high rise buildings as though he is thinking, contemplating the vista below.
Growth Shares

2 ASX shares to buy and hold for the next decade

I’m bullish about the long-term potential of these businesses…

Read more »

A woman crosses her hands in front of her body in a defensive stance indicating a trading halt.
Growth Shares

2 unstoppable ASX growth shares to buy and hold

These shares are positioned for strong growth over the next decade according to analysts.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Growth Shares

Here are the 3 Australian stocks I'd tell a new investor to buy asap

These shares could be top picks for new investors right now. Let's dig deeper into them.

Read more »

A businessman compares the growth trajectory of property versus shares.
Growth Shares

2 ASX giants to buy for decades of growth and dividends

Income or growth? Why not have both!

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Growth Shares

3 Australian shares to buy and hold for 20 more years

Let's see why these shares could be among the best to buy and hold until the 2040s.

Read more »